NOTE PURCHASE AGREEMENT dated as of July 6, 2008 among ANGIOTECH PHARMACEUTICAL INTERVENTIONS, INC., ARES CORPORATE OPPORTUNITIES FUND III, L.P., NEW LEAF VENTURES I, L.P. NEW LEAF VENTURES II, L.P. and, solely with respect to Article II, III, IV and...Note Purchase Agreement • July 10th, 2008 • Angiotech Pharmaceuticals Inc • Pharmaceutical preparations • New York
NOTE PURCHASE AGREEMENT, dated as of July 6, 2008 (this “Agreement”), among Angiotech Pharmaceutical Interventions, Inc., a Delaware corporation (the “Company”), and, solely with respect to Articles II, III, IV and V hereof, Angiotech Pharmaceuticals, Inc., a corporation organized under the laws of British Columbia, Canada (“Parent”), each party identified on the signature pages hereto under the heading “Subsidiary Guarantors” (the “Subsidiary Guarantors”) and Ares Corporate Opportunities Fund III, L.P., a Delaware limited partnership (“Ares”) and New Leaf Ventures I, L.P. (“New Leaf I”) and New Leaf Ventures II, L.P. (“New Leaf II” and, together with New Leaf I, “New Leaf”) (Ares and New Leaf, each a “Purchaser” and together, “Purchasers”).
